It's not every day that you hear about major medical advancements that can really, truly change peoples' lives in massive ways. Of course, the research into those advancements has long been ongoing, but it's always encouraging when the public can see the fruits of those labors.
In fact, exactly that has happened recently; on July 6, 2023, the FDA approved the drug lecanemab (also known by the brand name Leqembi), the first of its class to be effective against early Alzheimer's disease. If it's not already obvious, this is some pretty big news. Alzheimer's is one of the leading causes of death for older adults, and it's something that currently affects millions of Americans alone. Not only that but there hasn't been an effective way to slow the progression of the disease. But now? Not only do researchers have a better understanding of the causes behind Alzheimer's — something that could lead to even more treatments in the future — but those affected by it will have more time before symptoms become more severe. Beyond that, FDA approval should ultimately make it available through Medicare. Read more...
No comments:
Post a Comment